

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3987692

| | |
|---|---------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| ZUCAI SUO | 11/17/2015 |
| RECEIVING PARTY DATA | |
| Name: | NUCORION PHARMACEUTICALS, INC. |
| Street Address: | 2711 CENTERVILLE RD |
| Internal Address: | SUITE 400 |
| City: | WILMINGTON |
| State/Country: | DELAWARE |
| Postal Code: | 19808 |
| PROPERTY NUMBERS Total: 3 | |
| Property Type | Number |
| Application Number: | 14783199 |
| Application Number: | 61786501 |
| PCT Number: | US2014029929 |
| CORRESPONDENCE DATA | |
| Fax Number: | (949)760-9502 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 9497600404 |
| Email: | efiling@knobbe.com |
| Correspondent Name: | KNOBBE MARTENS OLSON & BEAR LLP |
| Address Line 1: | 2040 MAIN STREET |
| Address Line 2: | 14TH FLOOR |
| Address Line 4: | IRVINE, CALIFORNIA 92614 |
| ATTORNEY DOCKET NUMBER: | LIGAND.249PR/NP/WO |
| NAME OF SUBMITTER: | MARK D. MARSDEN |
| SIGNATURE: | /Mark D. Marsden / |
| DATE SIGNED: | 08/01/2016 |
| Total Attachments: 3 | |
| source=Suo to Nucorion LIGAND.249#page1.tif | |
| source=Suo to Nucorion LIGAND.249#page2.tif | |

ASSIGNMENT

WHEREAS, **Zucaí Suo**, residing at Dublin, Ohio, (individual(s) hereinafter "ASSIGNOR") owner by assignment of certain new and useful improvements, technology, inventions, developments, ideas, ornamental design or discoveries related to **SUBSTITUTED GEMCITABINE BICYCLIC AMIDE ANALOGS AND TREATMENT METHODS USING SAME** (collectively hereinafter referred to as the "Work") for which an application for Letters Patent in the United States has been prepared for filing (identified above) with the United States Patent and Trademark Office (hereinafter the "Application");


AND WHEREAS, **Nucorion Pharmaceuticals, Inc.**, a Delaware Corporation, (hereinafter the "ASSIGNEE"), desires to acquire the entire right, title, and interest in and to the Application and the Work:

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby acknowledges that ASSIGNOR has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto said ASSIGNEE, its successors, legal representatives and assigns, the entire right, title, and interest throughout the world in the Application and the Work, including all provisional applications relating thereto (including but not limited to U.S. Provisional Application No. 61/786,501, filed March 15, 2013), and all nonprovisional applications claiming priority thereto, including, all divisions, continuations, continuations-in-part, reissues, and reexaminations thereof, and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof, and all rights of priority under International Conventions and any related Letters Patent which may hereafter be granted or filed in any country or countries foreign to the United States, all extensions, renewals and reissues thereof, and all patents and applications listed in APPENDIX A; and ASSIGNOR hereby authorizes and requests the Commissioner of Patents of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all related Letters Patent to the ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND ASSIGNOR DOES HEREBY sell, assign, transfer, and convey to ASSIGNEE, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of said Letters Patent before or after issuance.

AND ASSIGNOR DOES HEREBY covenant and agree that ASSIGNOR will communicate to said ASSIGNEE, its successors, legal representatives and assigns, any facts known to ASSIGNOR respecting the Work, and testify in any legal proceeding, assist in the preparation of any other provisional or non-provisional applications relating to the Application and the Work or any improvements made thereto, sign all lawful papers, authorize the filing of and execute and make all rightful oaths and/or declarations in connection with the Application and the Work including any improvements made thereto, any patent applications filed therefrom, and any continuing application filed from any of the aforementioned applications, and generally do everything possible to aid the ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for the Work in all countries.

Legal Name of inventor: Zucai Suo

Signature:  Date: Nov. 17, 2015

Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.

APPENDIX A

| Title of Invention: | Country: | Application No. | Filing Date: |
|---|-----------------|---|---------------------|
| SUBSTITUTED GEMCITABINE BICYCLIC AMIDE ANALOGS AND TREATMENT METHODS USING SAME | CN | Chinese national phase of PCT/US2014/029929 | 11/13/15 |
| SUBSTITUTED GEMCITABINE BICYCLIC AMIDE ANALOGS AND TREATMENT METHODS USING SAME | EP | 14763946.2 | 10/12/15 |
| SUBSTITUTED GEMCITABINE BICYCLIC AMIDE ANALOGS AND TREATMENT METHODS USING SAME | US | 14/783199 | 10/08/15 |
| SUBSTITUTED GEMCITABINE BICYCLIC AMIDE ANALOGS AND TREATMENT METHODS USING SAME | WO | PCT/US2014/029929 | 03/15/14 |

22086937